Aviptadil ( DrugBank: Aviptadil )


5 diseases
IDDisease name (Link within this page)Number of trials
49Systemic lupus erythematosus7
51Scleroderma7
84Sarcoidosis1
85Idiopathic interstitial pneumonia1
86Pulmonary arterial hypertension8

49. Systemic lupus erythematosus


Clinical trials : 993Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

51. Scleroderma


Clinical trials : 525Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

84. Sarcoidosis


Clinical trials : 149Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

85. Idiopathic interstitial pneumonia


Clinical trials : 627Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

86. Pulmonary arterial hypertension


Clinical trials : 1,205Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries